Inogen, Inc (INGN) Covered Calls

Inogen, Inc. is a leading medical technology company that develops, manufactures, and markets innovative portable oxygen concentrators for patients with chronic respiratory conditions. The firm’s proprietary technology is designed to replace expensive and restrictive oxygen tanks with lightweight, travel-friendly devices. By providing medical-grade oxygen therapy that supports an active lifestyle, the company aims to improve the quality of life for users globally.

You can sell covered calls on Inogen, Inc to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for INGN (prices last updated Wed 4:16 PM ET):

Want to make money with covered calls?  Sign Up For A Free Trial

Inogen, Inc. is a pioneer in the respiratory care market, specifically recognized for transforming the way supplemental oxygen is delivered to patients. The company’s flagship products, such as the Inogen Rove 6, utilize pulse-dose technology to provide medical-grade oxygen in a lightweight, battery-powered format. This innovation has allowed millions of patients with Chronic Obstructive Pulmonary Disease (COPD) to maintain their independence and mobility without the logistical burden of traditional liquid or compressed oxygen tanks.

Strategic Diversification and 2026 Innovation

In 2026, the company is executing a "Respiratory Platform" strategy, expanding its reach beyond its core portable oxygen concentrator (POC) business. A major milestone in early 2026 was the commercial launch of the Aurora Masks, marking the firm’s entry into the $2.2 billion U.S. obstructive sleep apnea (OSA) market. Additionally, the company is ramping up the distribution of the Voxi 5, its next-generation stationary concentrator designed for quiet, energy-efficient home use. These launches are supported by a new patient portal designed to enhance digital health monitoring and improve clinical outcomes through real-time data sharing with healthcare providers.

Financially, the firm entered 2026 with a strengthened, debt-free balance sheet and a $30 million share repurchase authorization. Despite facing headwinds in the domestic rental segment, the company reported 4% year-over-year revenue growth for 2025, reaching approximately $349 million. Management is currently prioritizing "Channel Optimization," shifting more resources toward business-to-business (B2B) channels and international markets, which now represent roughly 40% of total sales. This shift is intended to drive higher unit volumes and improve operating leverage as the company moves toward sustained Adjusted EBITDA profitability.

Competitive Landscape

The respiratory and medical equipment market is highly competitive, with the company vying against large diversified healthcare firms and specialized technology providers. Key competitors include:

1. Avanos Medical, Inc.: A medical device company focused on digestive health and respiratory health solutions. They compete in the chronic care space, offering specialized medical devices that target overlapping patient populations in clinical and home settings.
2. MiMedx Group, Inc.: While primarily focused on placental biologics, they compete for institutional healthcare budgets and specialized clinic Mindshare within the regenerative and chronic care sectors.
3. Tactile Systems Technology, Inc.: A company that develops and markets medical devices for the treatment of lymphedema and chronic swelling. They compete in the home-based chronic disease management market, utilizing a high-touch direct-to-patient sales model similar to the company’s.
4. ResMed Inc.: A global leader in digital health and cloud-connected medical devices for sleep apnea and COPD. They are a primary competitor in the broader respiratory market, particularly as the company expands its presence in the CPAP and sleep therapy segments.

Strategic Outlook and Market Position

The firm is prioritizing the stabilization of its Direct-to-Consumer (DTC) segment by integrating AI-driven lead scoring and more efficient digital marketing spends. Strategic efforts in 2026 are also focused on the U.S. rollout of the Simeox airway clearance technology, which targets patients with cystic fibrosis and bronchiectasis. By diversifying its product portfolio to include OSA and airway clearance solutions, the company aims to mitigate the cyclicality of the POC market. Management remains committed to a long-term goal of high single-digit revenue growth and maintaining its leadership in "Intelligent Delivery Technology" for oxygen therapy.

Want more examples? INGM Covered Calls | INGR Covered Calls